WO2016155051A1 - 一种可还原降解聚两性离子纳米胶束及其制备方法 - Google Patents
一种可还原降解聚两性离子纳米胶束及其制备方法 Download PDFInfo
- Publication number
- WO2016155051A1 WO2016155051A1 PCT/CN2015/077150 CN2015077150W WO2016155051A1 WO 2016155051 A1 WO2016155051 A1 WO 2016155051A1 CN 2015077150 W CN2015077150 W CN 2015077150W WO 2016155051 A1 WO2016155051 A1 WO 2016155051A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nanomicelle
- zwitterionic
- terpolymer
- taurine
- cystamine
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/07—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media from polymer solutions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/02—Polyamines
Definitions
- the invention relates to the technical field of biomedical materials, in particular to a reductively degradable poly zwitterionic nanomicelle and a preparation method thereof.
- Nanomicelles as a chemotherapeutic drug carrier highlight a bright future in the field of malignant tumor treatment.
- Injectable nano-micelles, along with blood circulation, can pass through certain barriers of body tissues, reach the tumor site, release the drug at the lesion site, greatly improve the bioavailability of the drug and reduce toxic side effects.
- the ideal nanomicelle as a drug carrier needs to meet the following basic conditions: suitable micelle size, generally within 200 nm; stable in the long-term circulation in vivo, no non-specific protein adsorption; with a certain drug loading rate and targeting Controlled release characteristics; good biocompatibility and degradability.
- the outer layer of the micelle is usually modified with a hydrophilic material.
- a hydrophilic material is polyethylene glycol (PEG).
- PEG polyethylene glycol
- studies have shown that PEG has certain hydrophobicity in addition to hydrophilicity, and is oxidized in the presence of oxygen and transition metal ions (present in most biochemical-related solutions); possible immunization of PEG-modified protein drugs The reaction was also observed; in addition, the PEG shell shielding effect of the nanomicelles was not conducive to the uptake in the nanomicelle cells.
- poly-sex ions have unique anti-pollution properties.
- Common zwitterionic polyelectrolytes are: poly(sulfobetaine 2-methyl methacrylate) (PSBMA), poly(carboxybetaine 2-methyl methacrylate) (PCBMA), poly(2-methylpropene) Acyloxyethylphosphorylcholine (PMPC) and the like, as shown in Figure 1, have been identified as effective non-fouling materials which maintain the stability of micelles in complex media such as serum. Therefore, poly-zitter materials may be an excellent substitute for PEG.
- the polyazonia ions reported in the literature are usually obtained by polymerization of an ethylenic monomer containing positive and negatively charged groups. They are non-degradable, difficult to excrete in the body, and do not meet the requirements for use in human body. Application bottlenecks.
- an object of the present invention is to provide a reductively degradable poly zwitterionic nanomicelle having good biocompatibility, which can be completely degraded in the body without residue, and a preparation method thereof.
- the present invention provides a reductively degradable poly zwitterionic nanomicelle comprising a terpolymer synthesized from three monomers of N,N-bis(acryloyl)cystamine, a fatty amine and taurine, wherein the fatty amine
- the carbon chain length ranges from C8 to C16. If the carbon chain length is less than C8, the terpolymer is less hydrophobic and it is difficult to form micelles. If the carbon chain length is greater than C16, the solubility of the terpolymer will change.
- the sum of the number of moles of N,N-bis(acryloyl)cystamine in the terpolymer and the number of moles of fatty amine and taurine Equally, and the molar ratio of N,N-bis(acryloyl)cystamine, taurine and fatty amine in the terpolymer is from 1:0.2 to 0.9:0.8 to 0.1.
- the three monomer units have their respective functional roles in the nanomicelle: 1) N,N-bis(acryloyl)cystamine contains disulfide bonds, which are stable in a non-reducing environment, but in a reducing environment Breaking occurs, so that the micelles have reduction responsiveness; 2) fatty amines, non-toxic and harmless, soluble in solvents such as methanol and ethanol, have certain hydrophobicity, are often used in the synthesis of surfactants, and their hydrophobicity is high.
- the self-assembly and drug-loading properties of the material lay the foundation; 3) Taurine has many physiological functions and is an essential nutrient for human health. The taurine molecule contains both amino and sulfonic acid groups, and thus has zwitterionic properties. It also gives nanomicelles excellent anti-protein non-specific adsorption properties.
- the fatty amine used in the present invention is preferably one selected from the group consisting of dodecylamine having a carbon chain length of C12 as a monomer of the terpolymer, dodecylamine. It is a linear aliphatic primary amine with a relatively balanced hydrophobicity and solubility.
- the invention also provides a preparation method of the reductively degradable poly zwitterionic nanomicelle, which comprises the following steps in sequence:
- N, N-bis (acryloyl) cystamine, fatty amine and taurine three monomers by a copolycondensation reaction to obtain a terpolymer, the fatty amine carbon chain length range of C8-C16;
- the terpolymer is purified and dried, and the solvent is selected from tetrahydrofuran, or N,N-dimethylformamide, or dioxane, or isopropanol or absolute ethanol to obtain a terpolymer solution.
- the solvent is tetrahydrofuran, and tetrahydrofuran is a heterocyclic organic compound. It is one of the strong polar ethers and is used as a chemical reaction. a medium-polar solvent, a colorless, volatile liquid;
- the ternary copolymer solution obtained in the step 3) is subjected to dialysis treatment to obtain nano micelles.
- the reaction system of the copolycondensation reaction is a mixed solvent containing deionized water, methanol and ethanol.
- the volume ratio of the deionized water, methanol and ethanol is from 7:2:1 to 1.5, and the ratio of each component in the mixed solvent can be appropriately adjusted according to the reaction conditions.
- the reaction condition of the copolycondensation reaction is heating in a 50 ° C oil bath under nitrogen protection for not less than 3 days.
- the terpolymer is purified by dialysis, dried, and dissolved in tetrahydrofuran to obtain a terpolymer solution.
- a dialysis bag having a molecular weight cut off of 3,500 is used, and dialysis treatment is performed for not less than 48 hours to obtain nano micelles.
- the purpose of the dialysis bag is to remove unreacted small molecules and oligomers, because polymers with too low molecular weight are not easy to form micelles, and dialysis bags have various specifications, and 3500 can be selected.
- Michael addition is the addition reaction of a nucleophile to an ⁇ , ⁇ -unsaturated carbonyl compound.
- the N,N-bis(acryloyl)cystamine molecule contains a double bond, while the taurine and dodecylamine molecules contain a primary amino group, and a double bond with a primary amino group can undergo a typical Michael addition to form a polycondensation reaction product.
- a high molecular weight polymer can be obtained when the equimolar ratio of the two types of groups participating in the polycondensation reaction is obtained.
- the present invention adopts the molar ratio of N,N-bis(acryloyl)cystamine to the sum of the moles of taurine and dodecylamine, and N,N-bis(acryloyl)cystamine.
- the ratio of the moles of taurine to the fatty amine is from 1:0.2 to 0.9:0.8 to 0.1, whereby a high molecular weight copolymer is efficiently obtained.
- the copolymer segment contains structural units such as an amino group, a disulfide bond, and a zwitterion.
- the invention also provides a reductively degradable poly zwitterionic nanomicelle, which is used in the preparation of a chemotherapeutic drug carrier.
- Glutathione is a reducing tripeptide that is 100 to 1000 times more concentrated in tumor cells than in body fluids.
- the drug-loaded nanomicelle enters into the tumor cell. Under the reduction of glutathione, the disulfide bond in the polymer is broken, the polymer is degraded, and the drug is released; at the same time, the tumor cell has a weak acidic environment, the nanometer
- the micelle contains an amino group, so the nanomicelle has both pH and reducing sensitivity, and the micelle structure changes under the stimulation of the tumor cell environment, prompting drug release.
- the present invention has at least the following advantages:
- the copolymer segment contains structural units such as an amino group and a disulfide bond, it has sensitive pH and reduction responsiveness, and changes in micelle structure in a weakly acidic and reducing environment inside the tumor cell promotes the drug freed;
- the poly-zinc ions in the nano-micelles give the nano-micelles excellent anti-protein non-specific adsorption properties, so the nano-micelles have special anti-pollution properties;
- the disulfide bond is located in the polymer backbone, and after the nanomicelle enters the tumor cell, it is reduced under the stimulation of high concentration of glutathione in the cell, and the disulfide bond is broken, so the nanomicelle is completely degraded in the body, no Residue, as a carrier of anticancer drugs, has practical application value;
- Nanomicelles are non-cytotoxic and meet the safety standards for human use
- Figure 1 is a zwitterionic polyelectrolyte in the prior art
- Figure 2 is a schematic view showing the copolycondensation reaction of N,N-bis(acryloyl)cystamine, taurine and dodecylamine in the present invention
- FIG. 3 is a transmission electron micrograph of a reductively degradable poly zwitterionic nanomicelle in the present invention
- Figure 4 is a particle size distribution of the reductively degradable poly zwitterionic nanomicelles at pH 7.4 in the present invention
- a, b, c, d, and e represent N, N-bis(acryloyl)cystamine, taurine and dodecylamine in a molar ratio of 1:0.2:0.8, 1:0.5:0.5, respectively.
- Reducible degradable poly zwitterionic nanomicelle obtained by reaction at 1:0.6:0.4, 1:0.8:0.2, 1:0.9:0.1;
- Figure 5 shows the zeta potential of poly- zwitterionic nanomicelles as a function of pH
- the molar ratio of N,N-bis(acryloyl)cystamine, taurine and dodecylamine is 1:0.2:0.8;
- PBS and GSH represent a phosphate buffer solution and a glutathione solution, respectively;
- BSA bovine serum albumin
- FBS fetal bovine serum
- Figure 8 is a graph showing the cytotoxicity of reductively degradable poly zwitterionic nanomicelles in the present invention.
- cystamine dihydrochloride 11.6 g was added to a 250 mL single-necked flask, and then cystamine dihydrochloride was stirred and dissolved by adding 50 mL of distilled water.
- the flask was placed in an ice-water mixture at 0 ° C; 8 g of sodium hydroxide solid was weighed and dissolved in 20 mL of distilled water, and the dissolved sodium oxygen oxide solution was added to a single-mouth flask at a time, and the previously purified 19 mL was prepared.
- the acryloyl chloride was mixed with 3 mL of dichloromethane to form a solution, and the mixture was dropped into a one-necked flask through a constant pressure dropping funnel. After the dropwise addition was completed in 40 minutes, the reaction was controlled to react at 25 ° C for 16 hours.
- the product was filtered, washed with deionized water three times and then recrystallised from ethyl acetate.
- the product was dissolved in 10 mL of ultrapure water, transferred to a dialysis bag with a molecular weight cutoff of 3500-7000 D, dialyzed for 4 days, and then lyophilized to obtain poly(taurine-co-N,N-bis(acryloyl)cystamine. -co-dodecylamine) terpolymer.
- the copolycondensation reaction process of N,N-bis(acryloyl)cystamine, taurine and dodecylamine is shown in FIG.
- ae corresponds to the ternary copolymer of five kinds of ae in Table 1, and it can be seen that the nanomicelle has a substantially spherical shape.
- the particle size distribution is relatively uniform, but when the proportion of taurine in the component is large, the micelle morphology changes to a columnar shape.
- the ratio of the three monomers can be adjusted to obtain nano-micelles of different particle sizes.
- the proton is ingested, and the positive charge is artificially prepared.
- the negatively charged ions in the micelles are dominant, so they have a negative zeta potential value.
- the amino groups in the micelles take up protons to form ammonium-based positive ions, and as time increases, the degree of protonation increases, so the zeta potential is converted to a positively charged value.
- the reductively degradable poly zwitterionic nanomicelle obtained in Example 1 was placed in a glutathione solution having a concentration of 10 mM, wherein N,N-bis(acryloyl)cystamine in the nanomicelle: taurine: ten
- the molar ratio of diamine was 1:0.8:0.2, and the particle size change of the nanomicelle was tested by laser light scattering instrument at different times to observe the reduction responsiveness.
- the nanomicelle was free of glutathione.
- the particle size did not change after 24 hours; however, the nanomicelles in the 10 mM glutathione (GSH) solution showed a small particle size after 12 hours, indicating that there were some double
- the sulfur bond is broken, the molecular weight of the copolymer decreases, and the copolymer re-self-assembles to form nano-micelles with smaller particle size; as the nano-micelles increase in time in the GSH solution, more disulfide bonds are broken, and the copolymer Turning into a small molecule, the micelles tend to disintegrate, so the process of increasing the particle size occurs.
- Non-specific adsorption properties of anti-bovine serum albumin that can reduce polyphosphorus nano-micelles are not limited.
- BSA bovine serum albumin
- FBS fetal bovine serum
- 3T3 cells frozen at -80 ° C were quickly thawed, transferred to a centrifuge tube containing 7 mL of RPMI-1640 medium, centrifuged at 800 rpm, and containing 10% calf serum.
- the RPMI-1640 medium was pipetted into a single cell suspension, which was transferred to a 50 mL culture flask and incubated at 37 ° C in a 5% CO 2 incubator.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
- 一种可还原降解聚两性离子纳米胶束的制备方法,依次包括以下步骤:1)将N,N-双(丙烯酰基)胱胺、脂肪胺和牛磺酸三种单体通过共缩聚反应得到三元共聚物,所述脂肪胺的碳链长度范围为C8-C16;2)将三元共聚物经过纯化干燥后溶解,得到三元共聚物溶液;3)持续搅拌下,向三元共聚物溶液中滴加超纯水;4)将步骤3)得到的三元共聚物溶液,透析处理得到纳米胶束。
- 根据权利要求1所述的可还原降解聚两性离子纳米胶束的制备方法,其特征在于:所述步骤1)中,共缩聚反应的反应体系为包含去离子水、甲醇和乙醇的混合溶剂。
- 根据权利要求1所述的可还原降解聚两性离子纳米胶束的制备方法,其特征在于:所述脂肪胺为十二胺。
- 根据权利要求1所述的可还原降解聚两性离子纳米胶束的制备方法,其特征在于:所述步骤1)中,共缩聚反应的反应条件为氮气保护下50℃油浴锅加热不少于3天。
- 根据权利要求1所述的可还原降解聚两性离子纳米胶束的制备方法,其特征在于:所述步骤2)中,将三元共聚物经过透析纯化、干燥后,溶解于四氢呋喃中,得到三元共聚物溶液。
- 根据权利要求1所述的可还原降解聚两性离子纳米胶束的制备方法,其特征在于:所述步骤4)中,使用截留分子量为3500的透析袋,透析处理不少于48小时,得到纳米胶束。
- 根据权利要求1所述的可还原降解聚两性离子纳米胶束的制备方法,其特征在于:三种单体中,N,N-双(丙烯酰基)胱胺的摩尔数与脂肪胺和牛磺酸的摩尔数之和相等,并且N,N-双(丙烯酰基)胱胺、牛磺酸和脂肪胺的摩尔数之比为1∶0.2~0.9∶0.8~0.1。
- 一种可还原降解聚两性离子纳米胶束,其特征在于:包含由N,N-双(丙烯酰基)胱胺、脂肪胺和牛磺酸三种单体合成的三元共聚物,其中所述脂肪胺的碳链长度范围为C8-C16。
- 根据权利要求8所述的可还原降解聚两性离子纳米胶束,其特征在于: 所述三元共聚物中N,N-双(丙烯酰基)胱胺的摩尔数与脂肪胺和牛磺酸的摩尔数之和相等,并且所述三元共聚物中N,N-双(丙烯酰基)胱胺、牛磺酸和脂肪胺的摩尔数之比为1∶0.2~0.9∶0.8~0.1。
- 根据权利要求8或9任一项所述的可还原降解聚两性离子纳米胶束,在制备化疗药物载体中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015377981A AU2015377981B2 (en) | 2015-03-31 | 2015-04-22 | Reductively degradable polyzwitterionic nano-micelles and preparation method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510149728.5 | 2015-03-31 | ||
CN201510149728.5A CN104788689B (zh) | 2015-03-31 | 2015-03-31 | 一种可还原降解聚两性离子纳米胶束及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016155051A1 true WO2016155051A1 (zh) | 2016-10-06 |
Family
ID=53553905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/077150 WO2016155051A1 (zh) | 2015-03-31 | 2015-04-22 | 一种可还原降解聚两性离子纳米胶束及其制备方法 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN104788689B (zh) |
AU (1) | AU2015377981B2 (zh) |
WO (1) | WO2016155051A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105820334B (zh) * | 2016-05-19 | 2018-02-09 | 深圳百奥捷生物科技有限公司 | 一种基于氨基酸的聚两性离子纳米颗粒的制备方法 |
CN106750376B (zh) * | 2016-12-26 | 2018-09-28 | 江南大学 | 一种电荷可翻转的还原敏感可逆交联纳米胶束的制备方法 |
CN107007550B (zh) * | 2017-05-24 | 2020-06-26 | 上海中医药大学 | 一种氧化还原响应性两亲性共聚物及其制备方法和应用 |
CN107793573B (zh) | 2017-10-13 | 2020-08-11 | 江南大学 | 一种杂化双亲性星型共聚物纳米胶束的制备方法 |
CN111410757B (zh) | 2020-03-31 | 2021-09-07 | 江南大学 | 一种可降解及环境响应性复合物微凝胶的制备方法 |
CN111840573A (zh) | 2020-08-19 | 2020-10-30 | 江南大学 | 一种还原敏感性纳米胶束及其制备方法和应用 |
CN114307678A (zh) * | 2022-02-17 | 2022-04-12 | 天津工业大学 | 一种基于两性离子调控的复合纳滤膜的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102085177A (zh) * | 2011-01-12 | 2011-06-08 | 武汉理工大学 | 一种可还原降解纳米载药胶束及其制备方法 |
-
2015
- 2015-03-31 CN CN201510149728.5A patent/CN104788689B/zh active Active
- 2015-04-22 WO PCT/CN2015/077150 patent/WO2016155051A1/zh active Application Filing
- 2015-04-22 AU AU2015377981A patent/AU2015377981B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102085177A (zh) * | 2011-01-12 | 2011-06-08 | 武汉理工大学 | 一种可还原降解纳米载药胶束及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2015377981A1 (en) | 2016-10-20 |
CN104788689A (zh) | 2015-07-22 |
AU2015377981B2 (en) | 2017-04-20 |
CN104788689B (zh) | 2017-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016155051A1 (zh) | 一种可还原降解聚两性离子纳米胶束及其制备方法 | |
Oh et al. | A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: In vitro evaluation | |
Sang et al. | Preparation of pH/redox dual responsive polymeric micelles with enhanced stability and drug controlled release | |
US10933028B2 (en) | Method of preparing pH/reduction responsive polyamino acid zwitterionic nanoparticles | |
WO2018120544A1 (zh) | 一种电荷可翻转的还原敏感可逆交联纳米胶束的制备方法 | |
WO2017107486A1 (zh) | 可还原降解超支化聚合物纳米胶束及其制备方法和应用 | |
CN106265509A (zh) | 一种pH和Redox双响应两亲性嵌段共聚物及其制备方法和用途 | |
CN103656652B (zh) | 一种双敏感响应型聚合物纳米胶束及其制备方法和应用 | |
Wang et al. | Tailor-made gemcitabine prodrug nanoparticles from well-defined drug–polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy | |
Jazani et al. | Tumor-targeting intracellular drug delivery based on dual acid/reduction-degradable nanoassemblies with ketal interface and disulfide core locations | |
CN104817660A (zh) | 一种改性羧甲基壳聚糖纳米凝胶的制备 | |
Wan et al. | pH and reduction-activated polymeric prodrug nanoparticles based on a 6-thioguanine-dialdehyde sodium alginate conjugate for enhanced intracellular drug release in leukemia | |
CN105792814B (zh) | 用于药物递送的载有芳香族n-杂环的聚碳酸酯 | |
Pooresmaeil et al. | Development of the new pH-driven carrier from alginate/carboxymethyl starch bio-coated co-drugs@ COF-OH for controlled and concomitant colon cancer treatment | |
Li et al. | Redox-sensitive core cross-linked polyethylene glycol-polypeptide hybrid micelles for anticancer drug delivery | |
Zhang et al. | Synthesis of core-crosslinked zwitterionic polymer nano aggregates and pH/Redox responsiveness in drug controlled release | |
CN106349437B (zh) | 一种三嵌段聚合物、其制备方法及用途 | |
KR101818377B1 (ko) | 활성 산소종 관련 질환의 진단/치료용 디셀레나이드 가교결합을 함유한 블록 공중합체 및 이의 제조방법 | |
Li et al. | Reduction-responsive sulfur dioxide polymer prodrug nanoparticles loaded with irinotecan for combination osteosarcoma therapy | |
CN109432051B (zh) | 一种具有抗卵巢癌活性的靶向纳米粒及制备和应用 | |
Luan et al. | Injectable Chitosan Hydrogels Doped with 2D Peptide Nanosheet‐Drug Conjugates for Glutathione‐Responsive Sustained Drug Delivery | |
Chen et al. | Facile preparation of core cross-linked nanomicelles based on graft copolymers with pH responsivity and reduction sensitivity for doxorubicin delivery | |
CN106279678B (zh) | 一种可共价载药的还原敏感性纳米胶束的制备 | |
Jacobs et al. | Poly (N-vinylpyrrolidone-b-(γ-benzyl-l-glutamate))–synthesis and self-assembly into pH-sensitive micelles | |
Wang et al. | Facile fabrication of hyperbranched polyacetal quaternary ammonium with pH-responsive curcumin release for synergistic antibacterial activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2015377981 Country of ref document: AU Date of ref document: 20150422 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15887019 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 06/03/2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15887019 Country of ref document: EP Kind code of ref document: A1 |